Qiagen N.V. (NYSE:QGEN) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET

Company Participants

John Gilardi - VP, Head of Corporate Communications and IR
Thierry Bernard - CEO
Roland Sackers - CFO

Conference Call Participants

Patrick Donnelly - Citi
Odysseas Manesiotis - Berenberg
Matt Sykes - Goldman Sachs
Doug Schenkel - Wolfe Research
Aisyah Noor - Morgan Stanley
Michael Ryskin - Bank of America
Casey Woodring - JP Morgan
Andrew Brackmann - William Blair

Operator

Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining QIAGEN's Q3 2024 Earnings Conference Call Webcast [Operator Instructions]. At this time, I'd like to introduce your host, John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead.

John Gilardi

So thank you, operator. And thank you to all of you for joining us for our quarterly results call. We're pleased to have you with us and appreciate your interest in QIAGEN. This call is being webcast live and will be archived in the IR section of our Web site. You can also find a copy of the quarterly results, press release and the presentation on our Web site. Now I'd like to remind everyone that we will be discussing forward-looking statements on this call. Actual results may differ materially from those projected in any statements that we make. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F on file with the SEC and also available on our Web site. In addition, we will be referring to certain financial measures not prepared following generally accepted accounting principles or GAAP. We believe these non-GAAP measures provide useful information to investors. You can find a reconciliation in our release. All references to EPS refer to diluted EPS. So Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer, will start with some remarks on the key initiatives for the quarter, followed by a Q&A session. With that, let me hand over the call to Thierry.

Thierry Bernard

Thank you, John. Hello, and good morning, good afternoon or even good evening depending on when you are in the world, and thank you for joining us. I'm very pleased to share that our teams have once again exceeded our targets and delivered another solid quarter of results. Thanks to our heavily recurring revenues, which represent over 85% of our sales, we are very well on track to achieve our goals for 2024 in this still challenging macro environment. I want here to recognize the impact of our outstanding QIAGENers. But before we get into the performance of quarter three, let me take a moment to celebrate some truly remarkable achievements. 2024 is another year where our QIAGEN customers were awarded Nobel prizes for their invaluable contribution to advancing science and improving healthcare. This is a real testament to the impact of our customers on our daily lives. As we celebrate our 40th anniversary in 2024, we are more committed than ever to delivering the highest quality product that will support future noble price winners in helping to make improvements in life possible.